United States Biotechnology & Medical Research

Elicio Therapeutics Inc (ELTX)

Track

Elicio Therapeutics Inc has recorded no insider trading activity within the last three months. The most recent transaction occurred on December 22, 2023, when Yekaterina Chudnovsky purchased 1,213,000 shares. Prior to this, historical activity consisted of various buy and planned sale transactions by multiple insiders throughout 2021 and 2022.
Ticker: ELTX Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Elicio Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
2.3
Chudnovsky Yekaterina Non-Executive Director Large shareholder
Transaction date
Purchase
Price
259.84
Quantity 95,544 -3.6%
Value US$4,620,107
3.5
Venkatesan Jay See Remarks Executive Director
Transaction date
Purchase
Price
301.30
Quantity 6,657 -6.9%
Value US$2,430,470
3.5
Venkatesan Jay See Remarks Executive Director
Transaction date
Purchase
Price
73.32
Quantity 28,545 -23.5%
Value US$4,991,244
3.5
Venkatesan Jay See Remarks Executive Director
Transaction date
Purchase
Price
1.23
Quantity 50,000 +3.1%
Value US$61,500
2.0
Nissenson Allen Non-Executive Director
Transaction date
Purchase
Price
1.18
Quantity 2,037 +27.7%
Value US$2,404
2.0
Nissenson Allen Non-Executive Director
Transaction date
Purchase
Price
1.16
Quantity 7,346 +inf%
Value US$8,521
3.5
Venkatesan Jay See Remarks Executive Director
Transaction date
Purchase
Price
2.54
Quantity 3,527 +0.3%
Value US$8,976
3.3
Neylan John F. See Remarks Officer
Transaction date
Planned sale
Price
2.62
Quantity 358 -1.0%
Value US$938
3.5
Venkatesan Jay See Remarks Executive Director
Transaction date
Purchase
Price
2.54
Quantity 13,742 +1.0%
Value US$34,958
3.5
Venkatesan Jay See Remarks Executive Director
Transaction date
Purchase
Price
2.55
Quantity 27,883 +2.1%
Value US$70,993
3.5
Venkatesan Jay See Remarks Executive Director
Transaction date
Purchase
Price
2.41
Quantity 77,604 +6.3%
Value US$186,956
0.7
CURHAN GREGORY S See Remarks Officer
Transaction date
Purchase
Price
2.37
Quantity 4,000 +inf%
Value US$9,480
3.4
Rhodes Jennifer J See Remarks Officer
Transaction date
Planned sale
Price
2.42
Quantity 451 -1.5%
Value US$1,090
Goldberg Itzhak See Remarks Executive Director
Transaction date
Planned sale
Price
3.35
Quantity 32,118 -1.8%
Value US$107,721
Goldberg Itzhak See Remarks Executive Director
Transaction date
Planned sale
Price
3.39
Quantity 40,215 -2.2%
Value US$136,216
Goldberg Itzhak See Remarks Executive Director
Transaction date
Planned sale
Price
3.51
Quantity 38,800 -2.1%
Value US$136,328
Goldberg Itzhak See Remarks Executive Director
Transaction date
Planned sale
Price
3.54
Quantity 38,867 -2.1%
Value US$137,667
3.3
Neylan John F. See Remarks Officer
Transaction date
Planned sale
Price
4.13
Quantity 374 -1.0%
Value US$1,545
Goldberg Itzhak See Remarks Officer
Transaction date
Planned sale
Price
4.26
Quantity 38,495 -2.0%
Value US$163,808
Goldberg Itzhak See Remarks Officer
Transaction date
Planned sale
Price
4.17
Quantity 111,505 -5.5%
Value US$465,243
3.4
Rhodes Jennifer J See Remarks Officer
Transaction date
Planned sale
Price
4.40
Quantity 433 -1.4%
Value US$1,905
3.3
Neylan John F. See Remarks Officer
Transaction date
Planned sale
Price
8.62
Quantity 373 -1.0%
Value US$3,215
3.4
Rhodes Jennifer J See Remarks Officer
Transaction date
Planned sale
Price
8.65
Quantity 430 -1.4%
Value US$3,720
3.3
Neylan John F. See Remarks Officer
Transaction date
Planned sale
Price
13.20
Quantity 366 -1.0%
Value US$4,831
3.4
Rhodes Jennifer J See Remarks Officer
Transaction date
Planned sale
Price
13.92
Quantity 440 -1.3%
Value US$6,125
3.3
Neylan John F. See Remarks Officer
Transaction date
Planned sale
Price
13.55
Quantity 381 -1.0%
Value US$5,163
3.3
Neylan John F. See Remarks Officer
Transaction date
Sale
Price
19.13
Quantity 442 -1.1%
Value US$8,455
3.4
Rhodes Jennifer J See Remarks Officer
Transaction date
Sale
Price
20.45
Quantity 499 -1.4%
Value US$10,205
3.4
Rhodes Jennifer J See Remarks Officer
Transaction date
Sale
Price
19.54
Quantity 457 -1.3%
Value US$8,930
3.5
Venkatesan Jay See Remarks Executive Director
Transaction date
Sale
Price
16.00
Quantity 159,177 -11.6%
Value US$2,546,832
3.3
GANZI VICTOR F Non-Executive Director
Transaction date
Sale
Price
16.00
Quantity 246,720 -30.0%
Value US$3,947,520
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2023-12-26 2023-12-22 B Purchase
2.3
Chudnovsky Yekaterina
Non-Executive Director Large shareholder
95,544 -3.6%
259.84
US$4,620,107 		95,544 -3.6% 259.84 US$4,620,107
2022-05-27 2022-05-25 B Purchase
3.5
Venkatesan Jay

See Remarks

Executive Director
6,657 -6.9%
301.30
US$2,430,470 		6,657 -6.9% 301.30 US$2,430,470
2022-05-25 2022-05-24 B Purchase
3.5
Venkatesan Jay

See Remarks

Executive Director
28,545 -23.5%
73.32
US$4,991,244 		28,545 -23.5% 73.32 US$4,991,244
2022-05-25 2022-05-20 B Purchase
3.5
Venkatesan Jay

See Remarks

Executive Director
50,000 +3.1%
1.23
US$61,500 		50,000 +3.1% 1.23 US$61,500
2022-05-23 2022-05-20 B Purchase
2.0
Nissenson Allen
Non-Executive Director
2,037 +27.7%
1.18
US$2,404 		2,037 +27.7% 1.18 US$2,404
2022-05-23 2022-05-19 B Purchase
2.0
Nissenson Allen
Non-Executive Director
7,346 +inf%
1.16
US$8,521 		7,346 +inf% 1.16 US$8,521
2021-12-22 2021-12-20 B Purchase
3.5
Venkatesan Jay

See Remarks

Executive Director
3,527 +0.3%
2.54
US$8,976 		3,527 +0.3% 2.54 US$8,976
2021-12-21 2021-12-20 PlS Planned sale
3.3
Neylan John F.

See Remarks

Officer
358 -1.0%
2.62
US$938 		358 -1.0% 2.62 US$938
2021-12-20 2021-12-17 B Purchase
3.5
Venkatesan Jay

See Remarks

Executive Director
13,742 +1.0%
2.54
US$34,958 		13,742 +1.0% 2.54 US$34,958
2021-12-20 2021-12-16 B Purchase
3.5
Venkatesan Jay

See Remarks

Executive Director
27,883 +2.1%
2.55
US$70,993 		27,883 +2.1% 2.55 US$70,993
2021-12-17 2021-12-15 B Purchase
3.5
Venkatesan Jay

See Remarks

Executive Director
77,604 +6.3%
2.41
US$186,956 		77,604 +6.3% 2.41 US$186,956
2021-12-16 2021-12-15 B Purchase
0.7
CURHAN GREGORY S

See Remarks

Officer
4,000 +inf%
2.37
US$9,480 		4,000 +inf% 2.37 US$9,480
2021-12-15 2021-12-14 PlS Planned sale
3.4
Rhodes Jennifer J

See Remarks

Officer
451 -1.5%
2.42
US$1,090 		451 -1.5% 2.42 US$1,090
2021-12-07 2021-12-06 PlS Planned sale
Goldberg Itzhak

See Remarks

Executive Director
32,118 -1.8%
3.35
US$107,721 		32,118 -1.8% 3.35 US$107,721
2021-12-03 2021-12-03 PlS Planned sale
Goldberg Itzhak

See Remarks

Executive Director
40,215 -2.2%
3.39
US$136,216 		40,215 -2.2% 3.39 US$136,216
2021-12-03 2021-12-02 PlS Planned sale
Goldberg Itzhak

See Remarks

Executive Director
38,800 -2.1%
3.51
US$136,328 		38,800 -2.1% 3.51 US$136,328
2021-12-03 2021-12-01 PlS Planned sale
Goldberg Itzhak

See Remarks

Executive Director
38,867 -2.1%
3.54
US$137,667 		38,867 -2.1% 3.54 US$137,667
2021-11-22 2021-11-18 PlS Planned sale
3.3
Neylan John F.

See Remarks

Officer
374 -1.0%
4.13
US$1,545 		374 -1.0% 4.13 US$1,545
2021-11-17 2021-11-16 PlS Planned sale
Goldberg Itzhak

See Remarks

Officer
38,495 -2.0%
4.26
US$163,808 		38,495 -2.0% 4.26 US$163,808
2021-11-17 2021-11-15 PlS Planned sale
Goldberg Itzhak

See Remarks

Officer
111,505 -5.5%
4.17
US$465,243 		111,505 -5.5% 4.17 US$465,243
2021-11-16 2021-11-15 PlS Planned sale
3.4
Rhodes Jennifer J

See Remarks

Officer
433 -1.4%
4.40
US$1,905 		433 -1.4% 4.40 US$1,905
2021-10-20 2021-10-18 PlS Planned sale
3.3
Neylan John F.

See Remarks

Officer
373 -1.0%
8.62
US$3,215 		373 -1.0% 8.62 US$3,215
2021-10-15 2021-10-14 PlS Planned sale
3.4
Rhodes Jennifer J

See Remarks

Officer
430 -1.4%
8.65
US$3,720 		430 -1.4% 8.65 US$3,720
2021-06-21 2021-06-18 PlS Planned sale
3.3
Neylan John F.

See Remarks

Officer
366 -1.0%
13.20
US$4,831 		366 -1.0% 13.20 US$4,831
2021-05-18 2021-05-14 PlS Planned sale
3.4
Rhodes Jennifer J

See Remarks

Officer
440 -1.3%
13.92
US$6,125 		440 -1.3% 13.92 US$6,125
2021-04-20 2021-04-19 PlS Planned sale
3.3
Neylan John F.

See Remarks

Officer
381 -1.0%
13.55
US$5,163 		381 -1.0% 13.55 US$5,163
2021-03-19 2021-03-17 S Sale
3.3
Neylan John F.

See Remarks

Officer
442 -1.1%
19.13
US$8,455 		442 -1.1% 19.13 US$8,455
2021-03-16 2021-03-13 S Sale
3.4
Rhodes Jennifer J

See Remarks

Officer
499 -1.4%
20.45
US$10,205 		499 -1.4% 20.45 US$10,205
2021-02-17 2021-02-13 S Sale
3.4
Rhodes Jennifer J

See Remarks

Officer
457 -1.3%
19.54
US$8,930 		457 -1.3% 19.54 US$8,930
2021-02-11 2021-02-09 S Sale
3.5
Venkatesan Jay

See Remarks

Executive Director
159,177 -11.6%
16.00
US$2,546,832 		159,177 -11.6% 16.00 US$2,546,832
2021-02-11 2021-02-09 S Sale
3.3
GANZI VICTOR F
Non-Executive Director
246,720 -30.0%
16.00
US$3,947,520 		246,720 -30.0% 16.00 US$3,947,520
Explore more

More insider trading research around Elicio Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America